Evidence map›Paper›PMID 40581716›Full record

Observational studyEndocrine2025

Lenvatinib for unresectable anaplastic thyroid cancer: real-world experiences in multi-institutional study.

Takuya Mikoshiba, Mariko Sekimizu, Takeyuki Kono, Ryoto Nagai, Naoaki Ishikawa, Takashi Okada, Fumihiro Ito, Yoichiro Sato, Taiji Kawasaki, Noboru Habu and 1 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takuya MikoshibaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan. t-mikoshiba@keio.jp.ORCID 0000-0001-6206-6214
Mariko SekimizuDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Takeyuki KonoDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Ryoto NagaiDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Naoaki IshikawaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Takashi OkadaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Fumihiro ItoDepartment of Otolaryngology, National Tokyo Medical Center, Tokyo, Japan.
Yoichiro SatoDepartment of Otolaryngology, Saiseikai Utsunomiya Hospital, Tochigi, Japan.
Taiji KawasakiDepartment of Otolaryngology, Head and Neck Surgery, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.
Noboru HabuDepartment of Otolaryngology, Kyosai Tachikawa Hospital, Tokyo, Japan.
Hiroyuki OzawaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAnaplastic thyroid carcinoma (ATC) is a rare, aggressive malignancy with poor prognosis. Lenvatinib has demonstrated moderate efficacy and is approved for unresectable ATC treatment in Japan. However, some patients are unable to tolerate the standard 24 mg daily dose and require dose reductions or interruptions due to its high incidence of adverse effects. This study aimed to evaluate the therapeutic effects of lenvatinib in patients with ATC, particularly assessing outcomes with reduced dosages across multiple institutions.

methodsSixteen patients diagnosed with ATC and treated with lenvatinib were evaluated retrospectively. Overall survival (OS) and progression-free survival (PFS) were calculated. In addition, patients were divided into two groups based on 24 mg daily dose or reduced initial dose, and their therapeutic outcomes were compared.

resultsThe objective response rate was 31%, and the median OS and PFS were 2.2 and 1.7 months, respectively. Among the 16 patients, 11 (69%) initiated treatment with 24 mg daily, while the remaining 5 (31%) received a reduced dose. The median OS and PFS were 2.0 months and 1.4 months, respectively, among patients in the 24 mg daily group, compared to 6.2 months and 2.4 months, respectively, among patients in the reduced dosage group.

conclusionOur study demonstrated that lenvatinib has moderate efficacy for ATC. In addition, initiating treatment at a reduced dose could provide therapeutic benefit. Lenvatinib may serve as a treatment option for unresectable ATC when targeted therapies, including BRAF, RET, and NTRK inhibitors, are unavailable. Furthermore, although the standard 24 mg daily dose is recommended, a lower initial dosage may be effective for patients unable to tolerate the full dose.

Indexed as

Antineoplastic AgentsPhenylurea CompoundsQuinolinesThyroid Carcinoma, AnaplasticThyroid NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedProgression-Free SurvivalRetrospective StudiesTreatment OutcomeAntineoplastic AgentslenvatinibPhenylurea CompoundsQuinolinesAnaplastic thyroid cancerLenvatinibPrognosisReduced dosageThyroid cancer

Identifiers

PMID40581716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.